The trial of the autologous microbial therapy, MaaT011, met its primary endpoints through demonstration of…
MaaT PharmaMay 25, 2021
Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion…
MaaT PharmaMarch 29, 2021
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile…
MaaT PharmaMarch 17, 2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment…
MaaT PharmaMarch 11, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of…
MaaT PharmaDecember 22, 2020
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal…
MaaT PharmaDecember 7, 2020
MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
-- New investor Bpifrance leads Series B extension through the PSIM fund it manages on…
MaaT PharmaDecember 1, 2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe,…
MaaT PharmaNovember 25, 2020
MaaT033 is an oral formulation of MaaT Pharma’s full-ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy Lyon,…
MaaT PharmaNovember 12, 2020
